Study Reveals New Treatment for Periodontitis

RANDYPHOTOS/GETTYIMAGES

Researchers at Penn Dental School of Medicine and the National Institutes of Health have found a new treatment for periodontitis involving a drug the U.S. Food and Drug Administration has approved for psoriasis that blocks the activity of IL-17 and IL-23. Using a mouse-based study, investigators say high levels of these signaling molecules appear to contribute to periodontitis.

In the study, funded by the National Institutes of Dental and Craniofacial Research (NIDCR), researchers identified a mouse form of the human disease leukocyte adhesion deficiency, or LAD. This rare genetic disease causes recurrent bacterial infections and periodontitis in humans, according to the study published in the New England Journal of Medicine.

Led by Niki Moutsopoulos, DDS, PhD, of NIDCR, the team successfully treated a 19-year-old patient with LAD (a chronic nonhealing wound) and severe periodontitis by using the drug that blocks the activity of IL-23. According to the study, after 1 year of treatment, the patient’s periodontitis and skin wound had improved. “This is really exciting because we see that a treatment performed in mice in our laboratory directly paved the way to a novel clinical treatment for a serious disease that was not responsive to any other treatment,” says coauthor George Hajishengallis, DDS, PhD, the Thomas W. Evans Centennial Professor in Penn Dental’s Department of Microbiology.

Add a Comment

Your email address will not be published. Required fields are marked *

Dental, Dental Hygiene and Nursing Students Mark Their Entry Into Health Professions

What: University of Louisville dental, dental hygiene and undergraduate nursing students...

Standard Technology Allows Surgeons to Accurately Diagnose Remote Patients 

 The Cleft Palate-Craniofacial Journal – In today’s connected world, surgeons and...

Palmero Announces X-Ray Apron Recycle/Trade-in Program

Palmero Healthcare, a Hu-Friedy subsidiary, is pleased to announce our latest...

ClearCorrect Acquired by Global Dental Leader Straumann Group

ROUND ROCK, Texas, Aug. 17, 2017 (GLOBE NEWSWIRE) — ClearCorrect LLC,...

LANAP and LAPIP Protocols: Laser Gum Disease Protocols

Over 50% of US adults have gum disease.  Offer your patients...

IRIS HD USB 3.0 Intraoral Camera

Experience the Clarity in High Definition The new IRIS HD USB...

A New Adhesive/Primer Ideal for Indirect Restorations

At BISCO, adhesion is our passion. BISCO prides itself on developing...

KDZ Bruxer® Aesthetic

Bring the strength of full-contour zirconia into the facial zone with...